Jump to main content
Jump to site search

Molecular actions of hypocholesterolaemic compounds from edible mushrooms


Cholesterol levels are strictly regulated to maintain its homeostasis therefore, if it is not absorbed with the diet, the cholesterol biosynthetic pathway is enhanced and vice versa. Nowadays, the commonly prescribed therapeutic treatments for hypocholesterolemic patients are targeted toward the reduction of both cholesterol intestinal absorption and/or its endogenous biosynthesis. But, when hypercholesterolemia is still moderate the consumption of food products with cholesterol-lowering capacities is more desirable than drugs. The marketed food supplemented with hypocholesterolemic compounds are only inhibiting mechanisms for cholesterol absorption (i.e. phytosterols, cereal β-glucans). However, certain fungal extracts obtained from edible mushrooms might be able of modulating cholesterol levels by both strategies as pharmaceutical drugs and functional foods. In vitro and in vivo studies indicated that fungal sterols down-regulated genes involved in the cholesterol homeostasis (such as Srebf2 and Nr1h4 (FXR)) and other specific mushroom extracts (β-glucans and other water-soluble compounds) also stimulated transcriptional profiles similar to simvastatin or ezetimibe (two hypocholesterolemic drugs). These and other observations suggested that the hypocholesterolemic effect of mushrooms extracts could be due to transcriptional and post-transcriptional modulations besides other indirect effects.

Back to tab navigation

Publication details

The article was received on 08 Jun 2017, accepted on 07 Nov 2017 and first published on 08 Nov 2017

Article type: Review Article
DOI: 10.1039/C7FO00835J
Citation: Food Funct., 2017, Accepted Manuscript
  •   Request permissions

    Molecular actions of hypocholesterolaemic compounds from edible mushrooms

    A. Gil-Ramirez, D. Morales and C. Soler-Rivas, Food Funct., 2017, Accepted Manuscript , DOI: 10.1039/C7FO00835J

Search articles by author